Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Fineline Cube Apr 29, 2026
Company Drug

Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required

Fineline Cube Apr 29, 2026
Company

Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending

Fineline Cube Aug 16, 2023

Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and...

Company Deals

Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal

Fineline Cube Aug 16, 2023

Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to...

Company Drug

Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept

Fineline Cube Aug 16, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory...

Company Deals

Gilead Sciences Enters Collaboration with Tentarix Biotherapeutics for Polyspecific Antibodies

Fineline Cube Aug 16, 2023

Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix...

Company Deals

Amoy Diagnostics and AstraZeneca Expand Collaboration on Companion Diagnostic Development

Fineline Cube Aug 16, 2023

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced a new cooperation agreement with...

Company Drug

YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment

Fineline Cube Aug 16, 2023

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...

Company Drug

Everest Medicines’ Partner Venatorx Pharmaceuticals Receives FDA Priority Review for Cefepime-Taniborbactam

Fineline Cube Aug 16, 2023

China-based Everest Medicines (HKG: 1952) announced that its partner, Venatorx Pharmaceuticals, has received acceptance from...

Company

CStone Pharmaceuticals Reports 2023 Interim Financials and Business Milestones

Fineline Cube Aug 16, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced its 2023 interim financial results alongside key business...

Company Deals

HitGen Inc. Partners with Nested Therapeutics for Precision Medicine Research

Fineline Cube Aug 15, 2023

China-based HitGen Inc. (SHA: 688222) has announced a research service agreement with Cambridge, Massachusetts-based precision...

Company Drug

Simcere Pharmaceutical’s Cosela Receives NMPA Review for ES-SCLC Indication

Fineline Cube Aug 15, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Suzhou Leadsynbio Secures Series D Funding to Boost R&D and Market Presence

Fineline Cube Aug 15, 2023

Suzhou Leadsynbio Technology Co., Ltd, a specialist in synthetic biology, has reported raised hundreds of...

Company Drug

SinoMab BioScience Receives NMPA Approval for Phase I Clinical Study of SM17 Asthma Therapy

Fineline Cube Aug 15, 2023

Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that it has received...

Company Deals

Jiangsu Hengrui Pharmaceuticals Strikes Licensing Deal with One Bio Inc. for TSLP-Targeted mAb SHR1905

Fineline Cube Aug 15, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced a significant licensing agreement with...

Company Drug

J&J Subsidiary Janssen Wins FDA Approval for Akeega in BRCA-Positive mCRPC Treatment

Fineline Cube Aug 15, 2023

The US Food & Drug Administration (FDA) has granted marketing approval to Johnson & Johnson...

Company Drug

Medivir’s Fostrox in Combination with Lenvima Shows Promise in Phase IIa HCC Trial

Fineline Cube Aug 15, 2023

Sweden-based Medivir (STO: MVIR) has released interim data from a Phase IIa trial evaluating the...

Company Deals

AstraZeneca to Invest Additional USD 250 Million in Qingdao for Aerosol Production Plant

Fineline Cube Aug 15, 2023

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) is set to invest an additional USD 250...

Company Deals

Eli Lilly Expands Portfolio with Acquisitions of Sigilon Therapeutics and Versanis Bio

Fineline Cube Aug 15, 2023

Eli Lilly (NYSE: LLY) has completed the separate purchases of US compatriots Sigilon Therapeutics (NASDAQ:...

Policy / Regulatory

NHC Addresses Anti-Corruption Efforts in Pharmaceutical Industry Nationwide

Fineline Cube Aug 15, 2023

The National Health Commission (NHC) convened a conference to address questions on the ongoing anti-corruption...

Company Drug

Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 15, 2023

This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...

Company Deals

Novartis Acquires Chinook Therapeutics for $3.2 Billion, Eyes Kidney Disease Market

Fineline Cube Aug 14, 2023

Switzerland-based pharmaceutical major Novartis (NYSE: NVS) has successfully completed the scheduled purchase of US-based kidney...

Posts pagination

1 … 481 482 483 … 658

Recent updates

  • Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis
  • Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness
  • Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required
  • GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma
  • Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Company

Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness

Company Drug

Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required

Company Drug

GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.